Furthermore, a deeper understanding of the distinct roles and dynamics of FKBP51 isoforms offers the potential for more precise interventions in stress-related diseases, including metabolic dysfunctions, which are significant comorbidities in depression and arise as side effects of the commonly used psychopharmacological treatments. This evidence concerns the gene FKBP5 and depressive symptom measurement.